ASX:IMU Imugene (IMU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Imugene Stock (ASX:IMU) 30 days 90 days 365 days Advanced Chart Get Imugene alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12.70 million shsAverage VolumeN/AMarket Capitalization$290.84 millionP/E RatioN/ADividend Yield3.03%Price TargetN/AConsensus RatingN/A Company OverviewImugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.Read More… Receive IMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter. Email Address IMU Stock News HeadlinesImugene Issues Addendum to Extraordinary General Meeting NoticeMay 27 at 4:51 AM | tipranks.comImugene Limited Announces Extraordinary General Meeting for June 2025May 26 at 10:58 PM | tipranks.comMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 28, 2025 | Weiss Ratings (Ad)HotCopper Highlights Week 21: Trump jump for uranium; James Hardie, Imugene & moreMay 23, 2025 | msn.comImugene Limited Issues New Equity Securities as Part of Employee Incentive SchemeMay 23, 2025 | tipranks.comImugene Limited Announces Cessation of SecuritiesMay 21, 2025 | tipranks.comHotCopper Highlights, Week 18: Imugene's letter to investors; Dimerix & DatelineMay 2, 2025 | msn.comImugene Addresses Shareholder Concerns Amidst Market ChallengesApril 30, 2025 | tipranks.comSee More Headlines IMU Stock Analysis - Frequently Asked Questions How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) posted its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. Imugene had a negative net margin of 1,855.22% and a negative trailing twelve-month return on equity of 95.62%. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imugene investors own include Meta Platforms (META), NVIDIA (NVDA), Precision BioSciences (DTIL), Fortescue (FMG), Teladoc Health (TDOC), Viralytics (VRACY) and Whitehaven Coal (WHC). Company Calendar Last Earnings2/28/2019Today5/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:IMU CIKN/A Webwww.imugene.com Phone61 3 9824 5254FaxN/AEmployees110Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.68 million Net Margins-1,855.22% Pretax MarginN/A Return on Equity-95.62% Return on Assets-50.88% Debt Debt-to-Equity Ratio1.31 Current Ratio3.86 Quick Ratio15.17 Sales & Book Value Annual Sales$4.97 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.75 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares7,570,000,000Free FloatN/AMarket Cap$290.84 million OptionableNot Optionable Beta3.34 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (ASX:IMU) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.